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Background: There is currently a lack of randomized, sham-controlled trials that are adequately powered, using
validated outcomes, to allow for firm recommendations on the use of magnetic stimulation for stress urinary
incontinence. We report a protocol of a multicenter, randomized, double-blind, sham-controlled parallel-group
trial to evaluate the efficacy of magnetic stimulation for stress urinary incontinence.
Methods/Design: One hundred twenty subjects with stress urinary incontinence will be randomized in a 1:1
allocation to either active or sham magnetic stimulation using computer-generated, permuted blocks of variable
sizes. Subjects will receive 2 sessions of magnetic stimulation per week for 8 weeks (16 sessions total). The primary
outcome is the improvement in severity of involuntary urine loss based on the International Consultation on
Incontinence Questionnaire for Urinary Incontinence Short Form at the end of treatment sessions compared with
baseline. Secondary outcomes include cure, stress urinary incontinence–related symptoms (incontinence episode
frequency, urine loss in 1-hour pad test, pelvic floor muscle strength) and health-related quality of life (Patient
Global Impression of Improvement, International Consultation on Incontinence Questionnaire–Lower Urinary Tract
Symptoms Quality of Life and EQ-5D). The safety of magnetic stimulation will also be assessed. Besides evaluation
of clinical treatment effectiveness, cost-effectiveness analysis using patient-reported outcomes will be performed.
Discussion: This trial is designed to provide pending outcome information on this non-invasive treatment option.
We intend to acknowledge the existing flaws in previous clinical trials and determine conclusively whether magnetic
stimulation is effective for stress urinary incontinence.
Trial registration: ClinicalTrials.gov Identifier: NCT01924728. Date of Registration: 14 August 2013.
Keywords: Magnetic stimulation, Randomized controlled trial, Stress urinary incontinence, Study protocolBackground
Stress urinary incontinence (SUI) is a condition in which
there is an involuntary loss of urine on effort, physical
exertion, sneezing or coughing [1]. It is a chronic and
debilitating condition that affects the physical, psycho-
logical, social and economic well-being of affected indi-
viduals and their families [2] and substantially reduces
quality of life (QoL) similarly to severe chronic diseases
such as stroke, arthritis and chronic kidney disease [3,
4]. Prevalence estimates of urinary incontinence (UI) are* Correspondence: renly_lim@hotmail.com
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creativecommons.org/publicdomain/zero/1.0/disparate, ranging from 7 % to 53 % [5, 6], depending on
variables such as definition of UI used, survey population,
methodological and cultural differences, with SUI account-
ing for approximately 50 % of all incontinence [2].
The current guideline advocates pelvic floor muscle
training (PFMT) as the first-line conservative treatment
for SUI [7]. Use of other conservative therapeutic op-
tions, such as biofeedback, vaginal cones, electrical
stimulation and urethral plugs, is limited because of
their side effects, discomfort and invasiveness. Although
surgical interventions using midurethral slings have un-
questionably superior cure rates of approximately 90 %,
compared with 30 % in conventional physiotherapy [8],
some patients may be medically unfit for surgery,le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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adverse events related to surgery, such as bladder perfor-
ation, vaginal epithelial perforation and hematoma [8].
Indeed, when given a choice, most patients opt for
conservative treatments [9]. Treatment options should
therefore be based on the collaborative efforts between
patients and doctors, taking into account both the pa-
tient’s preferences and the surgeon’s judgment [10].
Given the high SUI prevalence and its overwhelming
negative impact on the QoL of patients, there is a need for
an acceptable therapeutic option with high efficacy. Many
subsequent studies have focused on developing novel, non-
invasive techniques to treat SUI, including the use of mag-
netic stimulation (MS). Several small studies, conducted in
the United States [11, 12], Japan [13–15], Korea [16] and
Turkey [17, 18], demonstrated that MS improved symp-
toms of SUI, with limited or no side effects. Additional file
1 provides a summary of published clinical trials on MS for
SUI in more detail. We recently conducted a systematic re-
view and found that most of the previous MS studies on
SUI had flaws, including lack of a placebo group, small
sample size, short or no follow-up and poor reporting [19].
The Fifth International Consultation on Incontinence
emphasized that no recommendation is possible based on
current evidence and that further research is needed to re-
duce the uncertainty around decision-making regarding the
use of MS [20]. Many key issues remain. Is MS effective for
female SUI? How many sessions are needed? How long can
the effects last? Is maintenance therapy required? To
answer these questions, a high-quality randomized con-
trolled trial is imperative. Thus, we designed a multicen-
ter, randomized, double-blind, sham-controlled trial with
the objective of evaluating whether patients with SUI
treated with MS have a higher continence rate than
sham-treated patients.
Aims of the study
The aim of the study is to investigate the effects of MS
in female patients with SUI. Furthermore, we intend to
show that MS therapy is safe and effective when pro-
vided in a community setting and to prove its overall
cost-effectiveness. The following research questions were
developed:
 What is the efficacy of MS in female patients with SUI?
 Does the use of MS lead to a better QoL in patients
with SUI?
 Is the use of MS cost-effective compared with the
conventional therapy?
 After the first 2 months of treatment:– How effective is active MS in patients who did
not respond to the initial sham treatment?
– Does longer treatment with active MS improve
treatment response in the initial active group?Methods/Design
Study design
This is a multicenter, randomized, double-blinded, sham-
controlled, parallel-group trial in a 1:1 allocation ratio. Po-
tential subjects will be screened from among patients
attending urology or obstetrics and gynecology clinics of
the participating hospitals in Northern Malaysia: Island
Hospital, Lam Wah Ee Hospital, Penang Adventist Hos-
pital, Pantai Hospital, Metro Specialist Hospital and Loh
Guan Lye Hospital, as well as from among the general
population through advertisements in posters, brochures,
newspapers and websites. The diagnosis of UI will be made
by either the urologist or the gynecologist [1]. Methods,
definitions and units conform to the standards jointly
recommended by the International Continence Society
and the International Urogynecological Association, except
where specifically noted [1]. The flowchart and study design
schedule are presented in Fig. 1 and Table 1, respectively.Study population
Inclusion criteria
To be eligible for participation, subjects are required to
fulfill the following conditions: (1) female aged 21 years
and older, (2) demonstration of urine leak on coughing
at a bladder volume of approximately 200 to 250 ml, (3)
International Consultation on Incontinence Question-
naire for Urinary Incontinence Short Form (ICIQ-UI-SF)
score of at least 6 points (range: 0–21), (4) must be able
and agree to carry out 1-hour pad test and (5) voluntary
participation and signing of the informed consent form.
Urodynamic testing will not be performed as an eligibility
criterion [21].Exclusion criteria
The following are the exclusion criteria: (1) patients with
urgency UI, mixed UI or overflow UI; (2) acute severe in-
fections (e.g., pneumonia); (3) severe cardiac arrhythmia;
(4) cardiac pacemaker or other implanted metallic devices;
(5) neurologic conditions (e.g., stroke, epilepsy, Parkinson
disease, multiple sclerosis); (6) random blood sugar above
10 mmol/L; (7) pregnant or actively trying to conceive; (8)
previous surgery for SUI; (9) pelvic or gynecological surgery
for less than 3 weeks or in the next 8 weeks; (10) previous
treatment with MS; (11) history of pelvic irradiation;
(12) concurrent medications with α-adrenergic antagonists
(e.g., terazosin, tamsulosin, doxazosin), diuretics, serotonin-
norepinephrine reuptake inhibitors or any other medica-
tions known to worsen incontinence; (13) stage III or IV
pelvic organ prolapse according to Pelvic Organ Prolapse
Quantification System [22]; (14) severe urethral sphincter
weakness and/or defect; (15) suspected urethral and/or
vesical fistula; (16) urinary tract infection or hematuria;
and/or (17) postvoid residual volume greater than 200 ml.
Fig. 1 Trial flowchart
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Table 1 Study design schedule
Screening and baseline Treatments Follow–up
Visit 0 1 2–7 8 9–15 16 17 18 19
Timeline (wk) 0 1 1–4 4 5–8 8 12 20 32
Screening for eligibility x
Informed consent x
Demographic data and medical history x
Physical examination x
Urine analysis x
Random blood sugar x
UPT x x
Uroflowmetry with postvoid residual (ultrasound) x x
Randomization x
MS treatment x x x x x
Adverse events x x x x x x x x
Retreatment or new intervention x x x
ICIQ-UI-SF x x x x x x
Incontinence episode diary x x x x x x
1-hr pad test x x x x x x
PFMF (perineometer) x x x x x x
PGI-I x x x x x
ICIQ-LUTS-QoL x x x x x x
EQ-5D x x x x x x
Blinding assessment x
Abbreviations: ICIQ-LUTS-QoL International Consultation on Incontinence Questionnaire–Lower Urinary Tract Symptoms Quality of Life, ICIQ-UI-SF International
Consultation on Incontinence Questionnaire for Urinary Incontinence Short Form, MS magnetic stimulation, PFMF pelvic floor muscle function, PGI-I Patient Global
Impression of Improvement, UPT urine pregnancy test
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Subjects of childbearing age who are not actively con-
ceiving are required to be on any effective contraception
methods, including (1) established use of oral, injected
or implanted hormonal methods of contraception; (2)
placement of an intrauterine device or intrauterine sys-
tem; (3) barrier methods of contraception, including
condom or occlusive cap (diaphragm or cervical or vault
caps) with spermicidal foam, gel, film, cream or supposi-
tory; (4) male sterilization (with the appropriate postva-
sectomy documentation of the absence of sperm in the
ejaculate); and (5) true abstinence.
Subjects who are taking α-adrenergic antagonists or
any other medications known to worsen incontinence
will be recruited into the study only if the medications
can be discontinued. If the medications can be discon-
tinued, the subjects will undergo a 14-day washout
period and then be reassessed for eligibility.
Subjects are prohibited from starting additional spe-
cific treatments for SUI, including PFMT, biofeedback,
vaginal cone, electrical stimulation or pharmacological
treatments such as duloxetine.Interventions
All subjects will be provided with counseling on lifestyle
modification, including (1) appropriate fluid consump-
tion (between 2 and 2.5 L/24 hr or approximately 250
ml/2 hr), (2) weight reduction if body mass index is 30
or higher and (3) caffeine reduction (limited to one to
two cups per day).
The intervention will involve the use of QRS-1010 Pel-
viCenter (QRS International, Ruggell, Liechtenstein)
(Fig. 2). This medical device uses electromagnetic puls-
ing technology for pelvic floor muscle stimulation, which
was approved as a conservative treatment for UI by the
U.S. Food and Drug Administration in June 1998 [11]
and by the European Commission in January 2011. It
generates a homogeneous magnetic field via a magnetic
coil embedded beneath the surface of the seat. When ap-
plied with high electric currents, the magnetic coil gen-
erates pulsed electromagnetic fields that are able to
penetrate deep into the pelvic floor to reach the relevant
conductive tissues. The changing magnetic field induces
a flow of ions to propagate electrical eddy currents. A
voltage gradient ensues, and membrane depolarization
Fig. 2 QRS-1010 PelviCenter magnetic stimulation device
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large membrane depolarization will result in an action
potential along the nerve tissues. In the pelvic floor, this
leads to pelvic floor nerve stimulation (stimulation of
motor end plates) and ultimately pelvic floor muscle
contraction [11, 23].
In both groups, treatment involves two sessions of 20 mi-
nutes each per week for 8 weeks (16 sessions total). After
the 8-week treatment, subjects who are not satisfied with
their treatment outcome will be given the opportunity to
enroll in an open-label phase, regardless of their treatment
allocation. Subjects will be considered treatment defaulters
if they miss treatments for more than 2 consecutive weeks.
Active magnetic stimulation
Subjects will be seated with the perineum in the middle of
the seat to allow for the greatest effect of the pulsing mag-
netic field on the pelvic floor and sphincter muscles. Stimu-
lation intensity will be gradually increased, beginning with
20 % simulation on the first session, followed by increments
of 20 % (or maximum tolerable stimulation) until they re-
ceive stimuli at 100 % intensity using a stimulation repeti-
tion cycle of 50 Hz in an 8-s “on” 4-s “off” pulsing manner
by a study nurse not involved in the assessments.
Sham magnetic stimulation
To ensure that sham subjects’ experiences are similar to
the intervention, the sham group will undergo the samenumber, duration and frequency of treatments as the
active group using the same MS device and stimula-
tion frequency. However, unlike the intervention, the
magnetic coil will be tilted to 22° down with a lower
stimulation intensity, beginning with 20 % simulation
intensity at the first session, followed by gradually
increasing increments of 20 % intensity after every five
sessions until a maximum of 60 % intensity is reached
(Fig. 3). The combination of these methods has been
shown to provide a total energy output of 136 kJ, (or
8.500 J each session) during the 8-week study period,
which is far less than the energy output of one
20-minute active mode run (at 100 % intensity) of 408




The primary outcome measure is the improvement in
the severity of involuntary urine loss. This is measured
by the self-administered ICIQ-UI-SF, which measures
frequency, volume and impact on daily life of involun-
tary urine loss. The ICIQ-UI-SF has undergone extensive
psychometric testing and is graded A (highly recom-
mended by the International Consultation of Incontin-
ence) as an outcome measure in research trials [24]. The
primary criterion for response is defined as having a 5-
point or greater reduction in the ICIQ-UI-SF score
(score range: 0–21) from baseline to 8 weeks [25–27].
The responder criterion of at least a 5-point decrease




As the ultimate aim of treatment is to achieve
complete continence, this is measured through
a combination of an objective and a subjective
outcome measure. Cure is defined as a leakage
of less than 1 g on the pad test [28] or a “never”
response to question 3 of the ICIQ-UI-SF, “How
often do you leak urine?”
2. SUI-related symptoms
a. Incontinence episode frequency (IEF)Symptoms relevant to SUI (incontinence episodes
and complications) will be measured using a
self-completed incontinence diary. The outcome
measure is the number of responders, defined as
having at least a 50 % reduction in IEF compared
with baseline [29]. The average daily incontinence
episode is calculated on the basis of a 3-day
incontinence episode diary.
b. 1-hour pad test
Fig. 3 Flux generator positions of active versus sham stimulation
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defined as having a decrease of 50 % or more in pad
weight compared with baseline [14]. The 1-hour
pad test will be conducted according to guidelines
published by the International Continence Society
[30]. However, the test will be initiated when the
bladder volume is at 250 ml (as measured by
abdominal ultrasound) instead of drinking 500 ml
of liquid. The modification is based on
recommendations from the Fifth International
Consultation of Incontinence, in which experimental
conditions for short-term pad tests must include a
standardized bladder volume [28]. Subjects are
judged as dry when leakage is less than 1 g on
the pad test and as improved when pad weight
decreases by 50 % or more [14, 28].
c. Pelvic floor muscle strength
The outcome measure will be an improvement
in the pelvic floor muscle strength compared
with baseline as measured using the Peritron
perineometer (LABORIE International,
Mississauga, ON, Canada) [31, 32]. The Peritron
is a pressure-sensitive dynamometer used for
objective assessment of the strength of pelvic
floor muscle contractions. For each subject, a
sterile latex sleeve is fitted around the silicone
rubber sheath and inserted into the vagina. After
restoring to point 0, the subjects will be asked to
perform a maximal pelvic floor contraction. After
each contraction, the calibrated 0 point will be
restored. The peak, average and duration of
contraction for three consecutive contractions
will be measured and recorded.
d. Incontinence severity
Subjects are divided into the following four
categories of SUI severity according to the
ICIQ-UI-SF score: slight (1–5), moderate (6–12),
severe (13–18) and very severe (19–21) [33]. Theoutcome measure will be the number of responders,
defined as at least one level of improvement in
severity groups (e.g., from moderate to mild).3. Quality of life (QoL)
Another measure of treatment success can be
defined as an improvement in the subjects’ QoL.
To ensure that these measures are captured and
reported, the following questionnaires will be used:
a. Patient Global Impression of Improvement
(PGI-I), a single-item generic measure that allows
subjects to rate their condition regarding their
response to the therapy. The outcome measure
is the number of responders, defined as subjects
who answer “very much better” and “much
better” to the PGI-I question [34].
b. The International Consultation on Incontinence
Questionnaire–Lower Urinary Tract Symptoms
Quality of Life, which is based on the King’s
Health Questionnaire [35], is a condition-specific
questionnaire used to evaluate the QoL of UI
patients. The possible score ranges from 19 to 76,
with higher values indicating increased impact
on QoL. The outcome measure will be an
improvement in the QoL of subjects compared
with baseline [35, 36].
c. The EQ-5D is a simple, generic QoL measure that
is able to provide a single index status. This will
be subsequently converted into a weighted health
state index using the Malaysian value sets.
Health economic evaluation and analysis
In addition to the evaluation of clinical treatment effect-
iveness, a prospective assessment of health economic is-
sues is being planned. A cost-effectiveness analysis using
patient-reported outcomes will be performed. To esti-
mate costs, the resource use is measured in natural units
(e.g., duration of treatment in minutes). The average re-
source use per patient is calculated and priced with
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prices or schedule prices (e.g., wage agreements for staff
costs). A sensitivity analysis is performed by replacing
the mean costs and effects with the upper and lower
bounds of the respective 95 % confidence intervals.
Costs and effectiveness results are synthesized in an in-
cremental cost-effectiveness ratio.
Safety and adverse events
MS has a good safety profile, with no reported adverse
effects [37]. Nevertheless, all adverse events, which in-
clude (but are not limited to) any unexpected signs and
symptoms, newly diagnosed disease, unusual laboratory
findings or hospitalizations, will be documented, regard-
less of whether the adverse event is related to MS. In
cases where there is deterioration in a subject’s preexist-
ing disease during the course of the study, this informa-
tion will also be documented as an adverse event.
During every follow-up visit, subjects will be asked if
they are experiencing any adverse effects.
Randomization
Subjects will be assigned in a 1:1 allocation to either the
active or sham MS group using computer-generated,
permuted block randomization, with variable block sizes
of four, six and eight, by an independent pharmacist with
no clinical involvement in the trial. Details of the allo-
cated group are given in sequentially numbered, opaque,
sealed envelopes to an appointed nurse involved in ad-
ministering the treatments to subjects. The independent
pharmacist who generates the randomization list will en-
sure that the envelopes are opaque and impermeable
when held to the light. Additionally, the sealed envelopes
are stored in a locked cabinet accessible only by the
appointed nurse. Enrollment of subjects (assessment of
eligibility, discussion of the trial, obtaining informed
consent) will be done by investigators and clinicians who
are blinded to treatment allocation. Following enroll-
ment of a subject, the investigator will assign the subject
a unique identification number. In the first treatment
session for each subject, the appointed study nurses will
sequentially open the envelopes. The subject’s unique
identification number and date will be written on the ap-
propriate allocated envelope.
Blinding and unblinding and control for bias
Investigators who carry out outcome measure assess-
ments and statisticians who perform data analysis will
not be informed of the allocation assignment. The same
appointed study nurses who sequentially open the treat-
ment allocation envelopes will be in charge of adminis-
tering treatments for the subjects during each visit, and
they will not be involved in any outcome assessments.
Formal training on operating the QRS-1010 PelviCenterwill be provided to the study nurses by an engineer from
QRS International. Additionally, treatment appointments
will be handled by the independent study nurses, and
the investigators will not come into contact with the
subjects at any time during the treatment sessions. All
personnel involved in the study will adhere to standard
operating procedures, with clear separation between in-
vestigators who conduct outcome assessments and study
nurses who administer the treatments.
In the event of an unexpected medical emergency,
subject allocation may be unblinded to the investigator
or clinician. The investigator will report the unblinding
to the sponsor, followed by submission of a detailed re-
port to the sponsor. The events in which unblinding
may occur include (but are not limited to) (1) the sub-
ject becomes pregnant while receiving the intervention;
(2) an adverse event requires unblinding to provide safety
information necessary to manage the subject’s condition;
and (3) a serious adverse event requires unblinding to de-
cide whether to continue or discontinue participation. An
unblinding report will be completed by the investigator,
with reasons for the unblinding specified.
Various measures will be taken to control for sources
of bias. For selection bias, differences between the base-
line characteristics of the two treatment groups will be
compared to ensure that randomization is accomplished
successfully. The appointed study nurse will sequentially
open the envelopes, which will be counterchecked by
another study nurse to ensure correct implementation of
treatment assignments. To avoid performance and de-
tection bias, the investigators are not allowed to be
present in the treatment room. The appointed nurses
who administer treatment will not be involved in enrol-
ling the patients or in any outcome measure assess-
ments. To evaluate the effectiveness of blinding of study
participants, each subject will be asked to answer the
following question at the end of the 16 treatment ses-
sions: Which treatment do you think you received? The
subject will have three possible answers: “active treat-
ment”, “don’t know” or “sham treatment”. Patients’ abil-
ity to correctly identify treatment assignment at the end
of the 8-week treatment will be analyzed and compared
between the two treatment groups. Finally, to control for
attrition bias, differences between the number of with-
drawals from the study, including the reasons for with-
drawal, will be analyzed and compared between the two
treatment groups.
Subject withdrawal
The subjects may choose to withdraw from the study, or
they may be withdrawn from the study, at any time at
the discretion of the investigator. If a subject withdraws
or is withdrawn, every effort will be made to complete
and report the observations as thoroughly as possible.
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not limited to) (1) subject’s decision, (2) intolerable ad-
verse events, (3) clinically significant laboratory abnor-
mality, (4) protocol violation (e.g., incorrectly enrolled or
randomized), (5) subject requires use of unacceptable
concomitant medication, (6) subject not compliant with
protocol procedures, (7) subject develops a condition
during the study that violates the inclusion and exclu-
sion criteria (e.g., pregnancy), (8) death and/or (9) any
other reason, in the investigator’s opinion, that would
impede the subject’s participation in the study.
In the event of pregnancy, the subject will be moni-
tored until the conclusion of the pregnancy, and the out-
come of the pregnancy will be reported. If a subject ends
her participation in the study before randomization
(before the first treatment visit), she will be replaced by
another randomly selected patient. If this happens, the




Two types of sample size calculations were performed:
non-repeated measures and repeated measures. Our pri-
mary outcome of interest is the difference in proportion of
responders between the active and sham groups after 8
weeks of treatment, defined as a reduction of 5 points or
more from baseline to 8 weeks in the ICIQ-UI-SF total
score. On the basis of outcomes derived from previously
published data on MS, it is anticipated that MS will im-
prove symptoms in 60 % (p1 = 0.6) of subjects with SUI,
whereas sham MS will improve symptoms in 30 % (p2 =
0.3) of subjects with SUI [11, 13]. Thus, a minimum sample
size of 88 (44 per arm) is powered to detect a difference of
at least 30 % (δ = 0.3), with a 95 % confidence interval (α =
0.05) and statistical power of 80 % (β = 0.2) [38]. Allowing
for a 25 % dropout rate, the enrollment goal is 120 subjects.
We also calculated our sample size using PASS13 Sam-
ple Size Software (NCSS Statistical Software, Kaysville,
UT, USA) [39]. The tests for two proportions in a
repeated-measures design, which can be used to calcu-
late sample size in a mixed-model analysis of repeated
measures data, was selected from among the PASS13
statistical tools. Using the same parameters (δ = 0.3,
α = 0.05 and β = 0.2), an autoregressive AR(1) covariance
pattern with autocorrelation of 1.0, and a design with six re-
peated measurements, a total sample size of 84 (n = 42 in
each arm) was obtained. As the sample size calculated
using a test of simple differences in proportion was higher,
we selected the initial calculated sample size.
Statistical analysis
Data entry will be performed using Excel 2007 software
(Microsoft, Redmond, WA, USA). IBM SPSS Statisticsfor Windows version 21.0 software (Armonk, NY, USA)
will be used to analyze the collected data. All statistical
analysis will be conducted by an independent statistician,
with blinding of assessors maintained. A p-value <0.05 is
considered statistically significant.
Descriptive statistics will be used to analyze baseline
characteristics. To compare baseline demographic data
between the treatment groups, independent t-tests (or
the Mann–Whitney U test) will be used to analyze con-
tinuous data, and χ2 or Fisher’s exact tests will be used
for categorical data.
In the main analysis, we will compare all subjects who
are randomized in this study on an intention-to-treat
basis, irrespective of whether they completed the allo-
cated treatments. Data will be analyzed by using a longi-
tudinal method (repeated-measures design). No missing
data imputation will be implemented (e.g., mean imput-
ation, last observation carried forward, multiple imput-
ation). Instead, a linear mixed model (LMM) and a
generalized linear mixed model (GLMM) that do not re-
quire formal imputation methods will be used [40]. Con-
tinuous dependent variables will be analyzed with LMM,
fitted with restricted maximum likelihood estimation
[41]. The multilevel approach (LMM and GLMM) will
be used, as it accounts for the non-independence among
observations in repeated-measures data and controls for
the effect of individuals by including extra parameters to
include any random effects [42]. Furthermore, a different
covariance matrix can be specified, providing enhanced
flexibility for longitudinal data analysis, as opposed to
the traditional repeated-measures analysis of variance
(ANOVA), which assumes compound symmetry (i.e.,
equal variances and covariances over time) [43]. Compound
symmetry means that the pattern of covariances or correla-
tions is constant across trials, which can be an unrealistic
assumption. Mauchly’s test of sphericity in repeated-
measures ANOVA is used to test whether sphericity (a less
stringent form of compound symmetry) is met. Repeated-
measures ANOVA must meet various assumptions, includ-
ing compound symmetry, balanced data and complete
dataset to ensure robust use.
The main outcome measure (responder analysis of ICIQ-
UI-SF, dichotomous variable) and other dichotomous
variables will be analyzed using GLMM (binomial logistic
regression). We will estimate the marginal means of pro-
portions, odds ratios comparing treatments and the corre-
sponding 95 % confidence intervals. The fixed effects
include time, code and interactions between code and time.
Code comprises two binary coded variables, with the sham
group set as the reference group. We are primarily inter-
ested in the code and time interaction, which represents
the difference in outcome variables between groups.
For responder analysis of outcome measures, subjects
who withdraw after randomization (missing data) will be
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the denominator. The responder analysis between treat-
ment groups will be compared using GLMM (binary
logistic regression).
Quality control and monitoring
Before commencing the trial, the protocol will be
reviewed and revised by all parties involved in the study,
including urologists, gynecologists and academicians. All
investigators and nurses involved in the clinical trial will
be trained on the study procedures and will attend the
Good Clinical Practice workshop before the start of the
trial. The current curriculum vitae and training records
of all investigators will be forwarded to the sponsor and
the ethics committee.
To maximize subject retention, timely reminders for ap-
pointments via telephone calls or text messages will be sent
by study investigators. Subjects who discontinue treatments
will be encouraged to return for follow-up. Nevertheless, in
the event of dropout or subject refusal of follow-up, the
subject’s decision will be acknowledged.
In accordance with the requirements of International
Conference on Harmonization Good Clinical Practice,
regular monitoring of the study will be carried out
throughout the study. The investigator accepts a moni-
toring representative from the sponsor to visit the
clinical trial centers regularly to ensure that the key re-
quirements of the study are met. The monitoring repre-
sentative will ascertain that the correct course of clinical
trial study is conducted and the case report forms are
accurate, reliable and complete.
To ensure patient confidentiality, all case report forms
and relevant documents will be kept in locked cabinets.
Each subject will be identified by a unique subject num-
ber. All files will be kept separately from identifying in-
formation used for subject tracking and follow-up
contacts. The results of the research will not become
part of the subject’s medical history and will be used
only for study purposes. The data published in reports,
publications or presentations will not disclose any iden-
tifying information.
Any adverse events that are encountered will be re-
corded in the case report form. Any serious adverse
events that occur during the course of the clinical trial
will be documented in the case report form and reported
within 24 hours of first knowledge of the event to the
sponsor and the ethics committee.
In the event of any injury resulting from the research
procedures, the sponsor assumes liability by law on
behalf of the investigators to compensate the cost of
medical treatment provided to the subjects. Financial
compensation is not available from the sponsor. The
cost of medical care of any illness or injury not directly
related to subjects’ participation in the study will not becompensated. An insurance policy is provided by the
sponsor of the study.
Ethics and dissemination
The study will be conducted in accordance with the
International Committee of Harmonization guidelines
for Good Clinical Practice and the Declaration of
Helsinki, and it has been approved by the Joint Ethics
Committee of the School of Pharmaceutical Sciences,
USM-Hospital Lam Wah Ee on Clinical Studies [USM-
HLWE/IEC/2013(0006)]. Written informed consent will be
obtained from each subject by the investigators before the
subject enters the trial.
During the course of the study, if important protocol
modifications are planned, amendments will be submit-
ted to the ethics committee for reapproval. A new writ-
ten consent form will be given to the subjects if the
changes concern them (such as changes in the duration
of treatment, changes in inclusion or exclusion criteria).
Only the investigators will have access to the final trial
dataset. The sponsor will have access to the final trial
dataset after all statistical analyses have been performed.
To disseminate our findings, the clinical trial results will
be published in peer-reviewed journals.
Discussion
Our trial is a prospective, randomized, double-blind,
sham-controlled trial of SUI using pulsed MS. The trial
is adequately powered and will use validated outcomes.
Previous studies conducted with MS had inherent flaws,
resulting in inconclusive evidence on this treatment mo-
dality. A search of trial registers indicates that there are
currently no ongoing, prospective clinical trials investi-
gating our research question of interest (last search done
on 5 December 2014).
There is a need for a high-quality randomized clinical
trial on this topic with a sham group, adequate sample
size, appropriate methodology and validated outcome
measures, as well as long-term follow-up [19]. We in-
tend to address the shortcomings of previous studies in
our trial and to obtain convincing evidence on the effi-
cacy of MS. We acknowledge the importance of applying
a sham MS as a control. We will use a specially designed
MS device for the purposes of this trial. The appearance
and noise are identical to the active treatment. The sum
of energy output of the 8-week sham treatment is lower
than the sum of energy output of one 20-minute active
mode run (K Dobler, personal communication). Further-
more, we will recruit only subjects who are naive to MS.
All subjects will be told that they may experience a tin-
gling sensation. Subjects will also be assessed for effect-
iveness of blinding at the end of the 8-week treatments.
To further allow for double-blinding, all assessors in-
volved in the study will be deliberately prohibited from
Lim et al. Trials  (2015) 16:279 Page 10 of 11entering the treatment room, and treatment will be co-
ordinated by independent study nurses. Collectively,
these measures allow better blinding of subjects with the
aim to diminish the placebo effects.
Next, we determined our sample size based on a
priori calculation to ensure that our study is ad-
equately powered to answer our primary outcome of
interest. To evaluate the effects of MS on SUI, we se-
lected various subjective and objective outcome mea-
sures as recommended by international guidelines [44,
45]. Further, we chose a patient-reported outcome, the
ICIQ-UI-SF questionnaire, as our primary outcome
measure because we recognize the importance of judg-
ing treatment benefit from a patient’s perspective [24].
We hope that use of standardized, internationally ac-
cepted tools will ease data pooling in meta-analyses,
limiting the number of high-quality clinical trials re-
quired to draw concrete conclusion on this treatment
option.
MS is a non-invasive procedure and has been shown
to be effective in SUI in various open-label studies
[23]. Further advantages are no reported adverse
events, unnecessary to undress, automatic contrac-
tions and no pain. If the efficacy of MS is better than
PFMT, which has a success rate of approximately 30
%, it may be a reasonable option for patients with SUI
who are not keen to undergo surgery. The results of
our trial are expected to add essential confirmatory
data regarding whether MS is effective for women
with SUI.
Our protocol has some limitations. To maximally ex-
clude any placebo effects, various considerations were
taken when designing the sham MS. We used the same
MS device, designed a coil that can be tilted to adjust
the strength of contractions, and included only subjects
who are naive to MS. Nevertheless, we think that our
blinding methods may be unsuccessful in some patients.
Selective refusal by participants in the present study may
limit the generalizability of the study results to the wider
public. Furthermore, when we first designed the trial, we
specified a follow-up period of 6 months for logistical
reasons. However, we intend to prolong our follow-up
period to a minimum of 1 year, as recommended by
guidelines [45]. Amendments have been made and sub-
mitted to our local ethics committee. Finally, we selected
our sample size based on our primary outcome data ana-
lysis method (responder analysis: percentage of subjects
who meet primary criterion of response). Our study may
be underpowered for determination of statistical signifi-
cance for the secondary outcome measures.
Trial status
The trial has completed its recruitment but is continuing
to follow-up patients.Additional file
Additional file 1: Summary of published magnetic stimulation
clinical trials on stress urinary incontinence. The table provides a
summary of previous studies conducted worldwide that were designed
to test the effects of magnetic stimulation on stress urinary incontinence.
The design of the trial, number of subjects, treatment protocol (including
intensity and frequency) and results are presented.
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